Product Description
Mechanisms of Action: GABA Mimetic
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Croatia | Cyprus | Czech | Greece | Hungary | Iceland | Ireland | New Zealand | Norway | Poland | Portugal | Slovenia | Spain | Sweden | Switzerland | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: KRANKENHAUSLEM DER EVANG. STADTMISSION HEIDELBERG GGMBH
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Schizophrenia|Depressive Disorder|Dementia|Tic Disorders|Psychophysiologic Disorders